chronic kidney disease
Conditions
Interventions
A:Huangkui Capsule, 2.5g, tid,for 24 weeks
B:Losartan, 50mg qd, for 24 weeks
C:Huangkui Capsule, 2.5g, tid+ losartan 50mg qd, for 24 weeks
Sponsors
Chinese General Hospital of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Renal biopsy proven primary glomeruli disease in 1 year; 2. Age range 18-70 years, male and female; 3. BP=60ml/min; 5. Proteinuria levels of 0.5 to 2.0g/24hr; 6. Signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Secondary glomeruli disease such as lupus nephritis, Henoch-Schonlein purpura nephritis, glomerulonephritis due to systemic small vessel vasculitis, diabetic nephropathy, hypertensive nephropathy, gouty nephropathy, myeloma kidney, et al; 2. The participants used the same treatment of traditional Chinese medicine or ACEI/ARB in the previous 4 weeks; 3. Received steroids/immunosuppressive drugs/Radix Tripterygii Wilfordii treatment for more than 3 months, and showed a poor clinical response; 4. With severe diseases in heart, brain, liver, kidney or hematopoietic system,as well as other diseases which seriously affected life ; 5. Pregnant or breast-feeding women; 6. Allergy history of Abelmoschus Manihot or losartan; 7. With poor compliance; 8. Participate in other clinical trials meanwhile; 9. Any other conditions that researchers think not suitable for this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24 hour urinary protein excretion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of serum cretinine, eGFR, serum albumin, CRP; | — |
Countries
China
Contacts
Public ContactXiangmei Chen
Outcome results
None listed